Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis

Beth Malcomson, Hollie Wilson, Eleonora Veglia, Gayathri Thillaiyampalam, Ruth Barsden, Shauna Donegan, Amal El Banna, Joseph S. Elborn, Madeleine Ennis, Catriona Kelly, Shu-Dong Zhang, Bettina C. Schock

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Cystic fibrosis (CF) lung disease is characterized by chronic and exaggerated inflammation in the airways. Despite recent developments to therapeutically overcome the underlying functional defect in the cystic fibrosis transmembrane conductance regulator, there is still an unmet need to also normalize the inflammatory response. The prolonged and heightened inflammatory response in CF is, in part, mediated by a lack of intrinsic down-regulation of the proinflammatory NF-κB pathway. We have previously identified reduced expression of the NF-κB down-regulator A20 in CF as a key target to normalize the inflammatory response. Here, we have used publicly available gene array expression data together with a statistically significant connections’ map (sscMap) to successfully predict drugs already licensed for the use in humans to induce A20 mRNA and protein expression and thereby reduce inflammation. The effect of the predicted drugs on A20 and NF-κB(p65) expression (mRNA) as well as proinflammatory cytokine release (IL-8) in the presence and absence of bacterial LPS was shown in bronchial epithelial cells lines (16HBE14o−, CFBE41o−) and in primary nasal epithelial cells from patients with CF (Phe508del homozygous) and non-CF controls. Additionally, the specificity of the drug action on A20 was confirmed using cell lines with tnfαip3 (A20) knockdown (siRNA). We also show that the A20-inducing effect of ikarugamycin and quercetin is lower in CF-derived airway epithelial cells than in non-CF cells.
LanguageEnglish
PagesE3725-E3734
Number of pages12
JournalProceedings of the National Academy of Sciences
Volume113
Issue number26
Early online date10 Jun 2016
DOIs
Publication statusPublished - 28 Jun 2016

Fingerprint

Cystic Fibrosis
Anti-Inflammatory Agents
Pharmaceutical Preparations
Epithelial Cells
Fibrosis
Inflammation
Cell Line
Cystic Fibrosis Transmembrane Conductance Regulator
Messenger RNA
Quercetin
Interleukin-8
Nose
Small Interfering RNA
Lung Diseases
Down-Regulation
Cytokines
Gene Expression
Proteins

Keywords

  • A20
  • NF-κB
  • connectivity mapping
  • drug repositioning
  • CF airway inflammation

Cite this

Malcomson, B., Wilson, H., Veglia, E., Thillaiyampalam, G., Barsden, R., Donegan, S., ... Schock, B. C. (2016). Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis. Proceedings of the National Academy of Sciences, 113(26), E3725-E3734. https://doi.org/10.1073/pnas.1520289113
Malcomson, Beth ; Wilson, Hollie ; Veglia, Eleonora ; Thillaiyampalam, Gayathri ; Barsden, Ruth ; Donegan, Shauna ; El Banna, Amal ; Elborn, Joseph S. ; Ennis, Madeleine ; Kelly, Catriona ; Zhang, Shu-Dong ; Schock, Bettina C. / Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis. In: Proceedings of the National Academy of Sciences. 2016 ; Vol. 113, No. 26. pp. E3725-E3734.
@article{81f43ff35db74f628e62d932033b2da1,
title = "Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis",
abstract = "Cystic fibrosis (CF) lung disease is characterized by chronic and exaggerated inflammation in the airways. Despite recent developments to therapeutically overcome the underlying functional defect in the cystic fibrosis transmembrane conductance regulator, there is still an unmet need to also normalize the inflammatory response. The prolonged and heightened inflammatory response in CF is, in part, mediated by a lack of intrinsic down-regulation of the proinflammatory NF-κB pathway. We have previously identified reduced expression of the NF-κB down-regulator A20 in CF as a key target to normalize the inflammatory response. Here, we have used publicly available gene array expression data together with a statistically significant connections’ map (sscMap) to successfully predict drugs already licensed for the use in humans to induce A20 mRNA and protein expression and thereby reduce inflammation. The effect of the predicted drugs on A20 and NF-κB(p65) expression (mRNA) as well as proinflammatory cytokine release (IL-8) in the presence and absence of bacterial LPS was shown in bronchial epithelial cells lines (16HBE14o−, CFBE41o−) and in primary nasal epithelial cells from patients with CF (Phe508del homozygous) and non-CF controls. Additionally, the specificity of the drug action on A20 was confirmed using cell lines with tnfαip3 (A20) knockdown (siRNA). We also show that the A20-inducing effect of ikarugamycin and quercetin is lower in CF-derived airway epithelial cells than in non-CF cells.",
keywords = "A20, NF-κB, connectivity mapping, drug repositioning, CF airway inflammation",
author = "Beth Malcomson and Hollie Wilson and Eleonora Veglia and Gayathri Thillaiyampalam and Ruth Barsden and Shauna Donegan and {El Banna}, Amal and Elborn, {Joseph S.} and Madeleine Ennis and Catriona Kelly and Shu-Dong Zhang and Schock, {Bettina C.}",
note = "UIR Compliant - dates added to PURE link",
year = "2016",
month = "6",
day = "28",
doi = "10.1073/pnas.1520289113",
language = "English",
volume = "113",
pages = "E3725--E3734",
journal = "Proceedings of the National Academy of Sciences",
issn = "0027-8424",
number = "26",

}

Malcomson, B, Wilson, H, Veglia, E, Thillaiyampalam, G, Barsden, R, Donegan, S, El Banna, A, Elborn, JS, Ennis, M, Kelly, C, Zhang, S-D & Schock, BC 2016, 'Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis', Proceedings of the National Academy of Sciences, vol. 113, no. 26, pp. E3725-E3734. https://doi.org/10.1073/pnas.1520289113

Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis. / Malcomson, Beth; Wilson, Hollie; Veglia, Eleonora; Thillaiyampalam, Gayathri; Barsden, Ruth; Donegan, Shauna; El Banna, Amal; Elborn, Joseph S.; Ennis, Madeleine; Kelly, Catriona; Zhang, Shu-Dong; Schock, Bettina C.

In: Proceedings of the National Academy of Sciences, Vol. 113, No. 26, 28.06.2016, p. E3725-E3734.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis

AU - Malcomson, Beth

AU - Wilson, Hollie

AU - Veglia, Eleonora

AU - Thillaiyampalam, Gayathri

AU - Barsden, Ruth

AU - Donegan, Shauna

AU - El Banna, Amal

AU - Elborn, Joseph S.

AU - Ennis, Madeleine

AU - Kelly, Catriona

AU - Zhang, Shu-Dong

AU - Schock, Bettina C.

N1 - UIR Compliant - dates added to PURE link

PY - 2016/6/28

Y1 - 2016/6/28

N2 - Cystic fibrosis (CF) lung disease is characterized by chronic and exaggerated inflammation in the airways. Despite recent developments to therapeutically overcome the underlying functional defect in the cystic fibrosis transmembrane conductance regulator, there is still an unmet need to also normalize the inflammatory response. The prolonged and heightened inflammatory response in CF is, in part, mediated by a lack of intrinsic down-regulation of the proinflammatory NF-κB pathway. We have previously identified reduced expression of the NF-κB down-regulator A20 in CF as a key target to normalize the inflammatory response. Here, we have used publicly available gene array expression data together with a statistically significant connections’ map (sscMap) to successfully predict drugs already licensed for the use in humans to induce A20 mRNA and protein expression and thereby reduce inflammation. The effect of the predicted drugs on A20 and NF-κB(p65) expression (mRNA) as well as proinflammatory cytokine release (IL-8) in the presence and absence of bacterial LPS was shown in bronchial epithelial cells lines (16HBE14o−, CFBE41o−) and in primary nasal epithelial cells from patients with CF (Phe508del homozygous) and non-CF controls. Additionally, the specificity of the drug action on A20 was confirmed using cell lines with tnfαip3 (A20) knockdown (siRNA). We also show that the A20-inducing effect of ikarugamycin and quercetin is lower in CF-derived airway epithelial cells than in non-CF cells.

AB - Cystic fibrosis (CF) lung disease is characterized by chronic and exaggerated inflammation in the airways. Despite recent developments to therapeutically overcome the underlying functional defect in the cystic fibrosis transmembrane conductance regulator, there is still an unmet need to also normalize the inflammatory response. The prolonged and heightened inflammatory response in CF is, in part, mediated by a lack of intrinsic down-regulation of the proinflammatory NF-κB pathway. We have previously identified reduced expression of the NF-κB down-regulator A20 in CF as a key target to normalize the inflammatory response. Here, we have used publicly available gene array expression data together with a statistically significant connections’ map (sscMap) to successfully predict drugs already licensed for the use in humans to induce A20 mRNA and protein expression and thereby reduce inflammation. The effect of the predicted drugs on A20 and NF-κB(p65) expression (mRNA) as well as proinflammatory cytokine release (IL-8) in the presence and absence of bacterial LPS was shown in bronchial epithelial cells lines (16HBE14o−, CFBE41o−) and in primary nasal epithelial cells from patients with CF (Phe508del homozygous) and non-CF controls. Additionally, the specificity of the drug action on A20 was confirmed using cell lines with tnfαip3 (A20) knockdown (siRNA). We also show that the A20-inducing effect of ikarugamycin and quercetin is lower in CF-derived airway epithelial cells than in non-CF cells.

KW - A20

KW - NF-κB

KW - connectivity mapping

KW - drug repositioning

KW - CF airway inflammation

U2 - 10.1073/pnas.1520289113

DO - 10.1073/pnas.1520289113

M3 - Article

VL - 113

SP - E3725-E3734

JO - Proceedings of the National Academy of Sciences

T2 - Proceedings of the National Academy of Sciences

JF - Proceedings of the National Academy of Sciences

SN - 0027-8424

IS - 26

ER -